CN101014579A - 用作ppar(过氧化物酶体增殖物激活受体)配体来治疗高脂血症和糖尿病的2-{-3-′2-(苯基)-唑-4-基甲氧基甲基-环已基甲氧基}-丙酸衍生物 - Google Patents

用作ppar(过氧化物酶体增殖物激活受体)配体来治疗高脂血症和糖尿病的2-{-3-′2-(苯基)-唑-4-基甲氧基甲基-环已基甲氧基}-丙酸衍生物 Download PDF

Info

Publication number
CN101014579A
CN101014579A CNA2005800271483A CN200580027148A CN101014579A CN 101014579 A CN101014579 A CN 101014579A CN A2005800271483 A CNA2005800271483 A CN A2005800271483A CN 200580027148 A CN200580027148 A CN 200580027148A CN 101014579 A CN101014579 A CN 101014579A
Authority
CN
China
Prior art keywords
formula
compounds
compound
acid
cyclohexylmethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800271483A
Other languages
English (en)
Chinese (zh)
Inventor
H·格隆比克
C·施塔帕尔
E·法尔克
S·凯尔
H-L·舍费尔
W·文德勒
S·克尼普斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN101014579A publication Critical patent/CN101014579A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA2005800271483A 2004-08-14 2005-07-30 用作ppar(过氧化物酶体增殖物激活受体)配体来治疗高脂血症和糖尿病的2-{-3-′2-(苯基)-唑-4-基甲氧基甲基-环已基甲氧基}-丙酸衍生物 Pending CN101014579A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004039533A DE102004039533B4 (de) 2004-08-14 2004-08-14 Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039533.0 2004-08-14

Publications (1)

Publication Number Publication Date
CN101014579A true CN101014579A (zh) 2007-08-08

Family

ID=35376939

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800271483A Pending CN101014579A (zh) 2004-08-14 2005-07-30 用作ppar(过氧化物酶体增殖物激活受体)配体来治疗高脂血症和糖尿病的2-{-3-′2-(苯基)-唑-4-基甲氧基甲基-环已基甲氧基}-丙酸衍生物

Country Status (21)

Country Link
US (1) US7538131B2 (https=)
EP (1) EP1789402B1 (https=)
JP (1) JP2008509894A (https=)
KR (1) KR20070046116A (https=)
CN (1) CN101014579A (https=)
AR (1) AR050121A1 (https=)
AT (1) ATE449086T1 (https=)
AU (1) AU2005274495A1 (https=)
BR (1) BRPI0514360A (https=)
CA (1) CA2576584A1 (https=)
DE (2) DE102004039533B4 (https=)
DK (1) DK1789402T3 (https=)
ES (1) ES2335513T3 (https=)
IL (1) IL181011A0 (https=)
MX (1) MX2007000846A (https=)
PA (1) PA8641601A1 (https=)
PE (1) PE20060643A1 (https=)
PT (1) PT1789402E (https=)
TW (1) TW200621733A (https=)
UY (1) UY29064A1 (https=)
WO (1) WO2006018118A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040199A2 (en) * 2001-08-31 2005-04-30 Aventis Pharma Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Also Published As

Publication number Publication date
MX2007000846A (es) 2007-04-17
WO2006018118A1 (de) 2006-02-23
AU2005274495A1 (en) 2006-02-23
ES2335513T3 (es) 2010-03-29
KR20070046116A (ko) 2007-05-02
ATE449086T1 (de) 2009-12-15
UY29064A1 (es) 2006-02-24
US7538131B2 (en) 2009-05-26
DE102004039533B4 (de) 2006-09-28
BRPI0514360A (pt) 2008-07-15
PT1789402E (pt) 2010-02-01
WO2006018118A8 (de) 2006-05-18
DE502005008552D1 (de) 2009-12-31
US20070197612A1 (en) 2007-08-23
CA2576584A1 (en) 2006-02-23
DE102004039533A1 (de) 2006-03-02
DK1789402T3 (da) 2010-03-22
TW200621733A (en) 2006-07-01
JP2008509894A (ja) 2008-04-03
AR050121A1 (es) 2006-09-27
PE20060643A1 (es) 2006-07-26
IL181011A0 (en) 2007-07-04
EP1789402A1 (de) 2007-05-30
PA8641601A1 (es) 2006-03-24
EP1789402B1 (de) 2009-11-18

Similar Documents

Publication Publication Date Title
US7872034B2 (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
US7598281B2 (en) Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes
US7160911B2 (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
CN100469761C (zh) 环烷基-取代的链烷酸衍生物、其制备方法及其作为药物的用途
CN101014579A (zh) 用作ppar(过氧化物酶体增殖物激活受体)配体来治疗高脂血症和糖尿病的2-{-3-′2-(苯基)-唑-4-基甲氧基甲基-环已基甲氧基}-丙酸衍生物
US7956077B2 (en) 2-{-3,′2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes
CN101193874A (zh) 作为ppar配体的6-唑-4-基甲氧基-烷氧基甲基取代的苯甲酸衍生物、其制备方法和其在药物制剂中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070808